MP24- 19- Cost Savings Achieved through Introduction of HOLEP and Care Pathway. by Johannes, James, MD et al.
Lehigh Valley Health Network
LVHN Scholarly Works
Department of Medicine
MP24- 19- Cost Savings Achieved through
Introduction of HOLEP and Care Pathway.
James Johannes MD
Lehigh Valley Health Network, James_R.Johannes@lvhn.org
Andrew Lai
Lehigh Valley Health Network, Andrew.Lai@lvhn.org
Angelo A. Baccala MD
Lehigh Valley Health Network, angelo_a.baccala@lvhn.org
Joseph Feliciano MD
Lehigh Valley Health Network, Joseph_R.Feliciano@lvhn.org
Clifford Georges MD
Lehigh Valley Health Network, Clifford_E.Georges@lvhn.org
See next page for additional authors
Follow this and additional works at: https://scholarlyworks.lvhn.org/medicine
Part of the Medical Sciences Commons, and the Urology Commons
This Poster is brought to you for free and open access by LVHN Scholarly Works. It has been accepted for inclusion in LVHN Scholarly Works by an
authorized administrator. For more information, please contact LibraryServices@lvhn.org.
Published In/Presented At
Johannes, J. Lai, A. Baccala, A. A., Feliciano, J. Georges, G. Steinbook, M. Voznesensky, M. (2017, September 12-16). MP24- 19- Cost
Savings Achieved through Introduction of HOLEP and Care Pathway. Poster Presented at: The World Congress of Endourology;
Endourological Society, Vancouver, BC, Canada.
Authors
James Johannes MD, Andrew Lai, Angelo A. Baccala MD, Joseph Feliciano MD, Clifford Georges MD, Melvin
Steinbook MD, and Maria Voznesensky MD
This poster is available at LVHN Scholarly Works: https://scholarlyworks.lvhn.org/medicine/1434
© 2017 Lehigh Valley Health Network
 
Studies have shown clinical benefits of Holmium Laser Enucleation of the Prostate (HOLEP) over TURP or other BPH procedures.  
Besides learning curve, high capital costs are a barrier to introduction.  Our objective is to investigate the impact on length of stay 
(LOS) as a source of cost savings compared to TURP, in the first 52 cases in a community hospital setting.
 For the first 52 patients, the mean age was 65.7.  HOLEP was performed for urinary retention in 32 patients and refractory urinary 
symptoms in 20.  Mean estimated prostate volume was 91.2 grams.  Mean resected volume of tissue was 33.5 (range 3-118cc) 
grams with 9.6% patients having malignant pathology.  3 month outcomes were comparable to larger series with IPSS overall and 
bother scores improving  from 22.5 to 6.9 (69%) and 4.6 to 1.7 (63%) respectively.  With our critical care pathway, length of stay 
averaged 10.7 hours including 6/52 (11.5%) requiring overnight stays.  Mean catheter time was 3.8 days.  This compared favorably 
to the mean TURP LOS during the same period of 36.5 hours.  This shows a  25.8 hour LOS benefit with HOLEP.  Based on then USA 
average daily cost of hospitalization of $2,271, this decreased LOS potentially generates a health system savings of $2,441.
CONCLUSIONS
 Implementation of a HOLEP program with a post-operative critical care pathway aimed at decreasing hospital length of stay significantly 
decreases hospital length of stay compared to TURP.  The estimated cost savings from this decreased LOS more than offset the capital 




 A prospectively managed database was maintained at the onset of starting a HOLEP program.  TURP data from our institution during 
the same period of time reviewed.  All HOLEP patients were managed post-operatively according to a critical care pathway specifically 
developed to minimize length of stay.  Patients underwent 2 hours of continuous bladder irrigation after which a clamping trial was 
performed.  Patients were ambulated with the catheter and clinically evaluated.  Patients were discharged home on POD 0 with a 
catheter if clinically appropriate.  Patients were seen in the office 2-3 days post-op for a trial of void.  To determine cost savings from 
decreased LOS, hospital expenses were sourced from the Henry J. Kaiser Family Foundation.
METHODS
Table 1. Pre-op Demographics (HOLEP)
 
Number of patients 52
Mean Age 65.7
Mean Pre-op IPSS 20.3
Mean Pre-op IPSS Bother 4.4
Mean Pre-op Estimated Prostate Volume 91.2
Pre-op Medications (%) 
Alpha blocker 96% (50)
5AR 40% (21)
Alpha and 5AR 31% (16)
ACH/B3 agonist 12% (6)
Primary HOLEP Indication
Catheter Dependent Retention 32
Refractory luts 20
Table 2. Peri-Operative Outcomes
 
Mean Resected Volume 33.5 gm
Mean Operative Time, Total (min) 92
Mean Resection Time (min) 67
Mean Morcellation Time (min) 10
Mean Length of Stay (hours 10.7
% Pts. Requiring Overnight Stay 11.50%
Mean Foley Time (days) 3.8
Figure 1: Post-HOLEP Care Pathway Figure 2: Change in QMax/PVR
Following HOLEP
Figure 3: Change in IPSS
Following HOLEP
Figure 4: Cost Comparison
in LOS Dollars
Surgery Completion - 24F 3-way foley to 
continuous bladder irrigation
Concerning hematuria/clots
Admitted overnight for CBI
Urine is clear/mild hematuria
Discharged home
Patient Evaluated











HOLEP (10.7 hr LOS) TURP (36.5 hr LOS) Savings of HOLEP over
TURP (25.8 hr LOS)
Pre-op 3m 6m
PVR 205 51.8 91
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